Modulation of α7 nicotinic acetylcholine receptor and fibrillar amyloid-β interactions in Alzheimer's disease brain

Journal of Alzheimer's Disease

Volumn 33, Issue 3, 2013, Pages 841-851

  Ni, Ruiqing ^a   Marutle, Amelia ^a   Nordberg, Agneta ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; fibrillar amyloid ; postmortem brain; 7 nicotinic acetylcholine receptors

Indexed keywords

ALPHA BUNGAROTOXIN; AMYLOID BETA PROTEIN; BUNGAROTOXIN RECEPTOR; CYTISINE; DIHYDRO BETA ERYTHROIDINE; GALANTAMINE; MECAMYLAMINE; MEMANTINE; METHYLLYCACONITINE; VARENICLINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BINDING KINETICS; BRAIN LEVEL; BRAIN TISSUE; CONTROLLED STUDY; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; NEUROMODULATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TISSUE HOMOGENATE;

EID: 84872441075     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-121447     Document Type: Article

References (62)

1. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356. (Pubitemid 34790756)
2. Albuquerque EX, PereiraEF, Alkondon M, RogersSW(2009) Mammalian nicotinic acetylcholine receptors: From structure to function. Physiol Rev 89, 73-120.
3. Taly A, Corringer PJ, Guedin D, Lestage P, Changeux JP (2009) Nicotinic receptors: Allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov 8, 733-750.
4. Thomsen MS, Hansen HH, Timmerman DB, Mikkelsen JD (2010) Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: From animal models to human pathophysiology. Curr Pharm Des 16, 323-343.
5. Paterson D, Nordberg A (2000) Neuronal nicotinic receptors in the human brain. Prog Neurobiol 61, 75-111. (Pubitemid 30100404)
6. Kadir A, Almkvist O, Wall A, Langstrom B, Nordberg A (2006) PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. Psychopharmacology (Berl) 188, 509-520. (Pubitemid 46758966)
7. Bao F, Wicklund L, Lacor PN, Klein WL, Nordberg A, Marutle A (2012) Different beta-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiol Aging 33, 825.e1-13.
8. Buckingham SD, Jones AK, Brown LA, Sattelle DB (2009) Nicotinic acetylcholine receptor signalling: Roles in Alzheimer's disease and amyloid neuroprotection. Pharmacol Rev 61, 39-61.
9. Wang HY, Lee DHS, D'Andrea MR, Peterson PA, Shank RP, Reitz AB (2000) beta-amyloid(1-42) binds to alpha 7 nicotinic acetylcholine receptor with high affinity - Implications for Alzheimer's disease pathology. J Biol Chem 275, 5626-5632. (Pubitemid 30115201)
10. Nagele RG, D'Andrea MR, Anderson WJ, Wang HY (2002) Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience 110, 199-211. (Pubitemid 34214939)
11. Pettit DL, Shao Z, Yakel JL (2001) beta-Amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice. J Neurosci 21, RC120.
12. DineleyKT, Bell KA, Bui D, Sweatt JD (2002) beta -Amyloid peptide activates alpha7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Biol Chem 277, 25056-25061. (Pubitemid 34951810)
13. Lamb PW, Melton MA, Yakel JL (2005) Inhibition of neuronal nicotinic acetylcholine receptor channels expressed in Xenopus oocytes by beta-amyloid1-42 peptide. J Mol Neurosci 27, 13-21.
14. Pym L, Kemp M, Raymond-Delpech V, Buckingham S, Boyd CAR, Sattelle D (2005) Subtype-specific actions of -amyloid peptides on recombinant human neuronal nicotinic acetylcholine receptors (-7,-4-2,-3-4) expressed in Xenopus laevisoocytes. Br J Pharmacol 146, 964-971.
15. Dougherty JJ, Wu J, Nichols RA (2003) Beta-amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. J Neurosci 23, 6740-6747. (Pubitemid 36951200)
16. Liu QS, Kawai H, Berg DK (2001) beta-Amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci U S A 98, 4734-4739. (Pubitemid 32295045)
17. Lee DH,Wang HY (2003) Differential physiologic responses of alpha7 nicotinic acetylcholine receptors to beta-amyloid1-40 and beta-amyloid1-42. J Neurobiol 55, 25-30. (Pubitemid 36396959)
18. Bokvist M, Lindstrom F, Watts A, Grobner G (2004) Two types of Alzheimer's beta-amyloid (1-40) peptide membrane interactions: Aggregation preventing transmembrane anchoring versus accelerated surface fibril formation. J Mol Biol 335, 1039-1049. (Pubitemid 38091609)
19. Lilja AM, Porras O, Storelli E, Nordberg A, Marutle A (2011) Functional interactions of fibrillar and oligomeric amyloid-beta with alpha7 nicotinic receptors in Alzheimer's disease. J Alzheimers Dis 23, 335-347.
20. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD (2001) Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 21, 4125-4133. (Pubitemid 32538537)
21. Hernandez CM, Kayed R, Zheng H, Sweatt JD, Dineley KT (2010) Loss of alpha7 nicotinic receptors enhances betaamyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. J Neurosci 30, 2442-2453.
22. Dziewczapolski G, Glogowski CM, Masliah E, Heinemann SF (2009) Deletion of the alpha7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease. J Neurosci 29, 8805-8815.
23. Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang GF, Shao L, DeKosky ST, Price JC, Mathis CA (2005) Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 25, 10598-10606. (Pubitemid 41681907)
24. Nordberg A, Rinne JO, Kadir A, Langstrom B (2010) The use of PET in Alzheimer disease. Nat Rev Neurol 6, 78-87.
25. Kadir A, Marutle A, Gonzalez D, Scholl M, Almkvist O, Mousavi M, Mustafiz T, Darreh-Shori T, Nennesmo I, Nordberg A (2011) Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. Brain 134, 301-317.
26. Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204-1222.
27. McLaurin J, Chakrabartty A (1996) Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity. J Biol Chem 271, 26482-26489. (Pubitemid 26359045)
28. Verdier Y, Zarandi M, Penke B (2004) Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: Binding sites and implications for Alzheimer's disease. J Pept Sci 10, 229-248. (Pubitemid 38594184)
29. Feuerbach D, Nozulak J, Lingenhoehl K, McAllister K, Hoyer D (2007) JN403, in vitro characterization of a novel nicotinic acetylcholine receptor alpha7 selective agonist. Neurosci Lett 416, 61-65. (Pubitemid 46428016)
30. Arias HR, Gu RX, Feuerbach D, Wei DQ (2010) Different interaction between the agonist JN403 and the competitive antagonist methyllycaconitine with the human alpha7 nicotinic acetylcholine receptor. Biochemistry 49, 4169-4180.
31. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD 3rd, O'Neill BT (2005) Varenicline: An alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48, 3474-3477. (Pubitemid 40664098)
32. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, NairnAC, SalterMW, Lombroso PJ, Gouras GK, Greengard P (2005) Regulation ofNMDA receptor trafficking by amyloidbeta. Nat Neurosci 8, 1051-1058. (Pubitemid 41061516)
33. Yu WF, Guan ZZ, Bogdanovic N, Nordberg A (2005) High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: A possible association with neuritic plaques. Exp Neurol 192, 215-225. (Pubitemid 40208555)
34. Small DH, Maksel D, Kerr ML, Ng J, Hou X, Chu C, Mehrani H, Unabia S, Azari MF, Loiacono R, Aguilar MI, Chebib M (2007) The beta-amyloid protein of Alzheimer's disease binds to membrane lipids but does not bind to the alpha7 nicotinic acetylcholine receptor. J Neurochem 101, 1527-1538. (Pubitemid 46848846)
35. Khan GM, Tong M, Jhun M, Arora K, Nichols RA (2010) beta-Amyloid activates presynaptic alpha7 nicotinic acetylcholine receptors reconstituted into amodel nerve cell system: Involvement of lipid rafts. Eur J Neurosci 31, 788-796.
36. Wang HY, Bakshi K, Frankfurt M, Stucky A, Goberdhan M, Shah SM, Burns LH (2012) Reducing amyloid-related Alzheimer's disease pathogenesis by a small molecule targeting filamin a. J Neurosci 32, 9773-9784.
37. Puzzo D, Privitera L, Fa M, Staniszewski A, Hashimoto G, Aziz F, Sakurai M, Ribe EM, Troy CM, Mercken M, Jung SS, Palmeri A, Arancio O (2011) Endogenous amyloid-beta is necessary for hippocampal synaptic plasticity and memory. Ann Neurol 69, 819-830.
38. Kudo Y, Okamura N, Furumoto S, Tashiro M, Furukawa K, Maruyama M, Itoh M, Iwata R, Yanai K, Arai H (2007) 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: A novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med 48, 553-561. (Pubitemid 47571409)
39. Tong M, Arora K, White MM, Nichols RA (2011) Role of key aromatic residues in the ligand-binding domain of alpha7 nicotinic receptors in the agonist action of beta-amyloid. J Biol Chem 286, 34373-34381.
40. Puzzo D, Privitera L, Leznik E, Fa M, Staniszewski A, Palmeri A, ArancioO(2008) Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 28, 14537-14545.
41. Liu Q, Huang Y, Xue F, Simard A, DeChon J, Li G, Zhang J, Lucero L, Wang M, Sierks M, Hu G, Chang Y, Lukas RJ, Wu J (2009) A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. J Neurosci 29, 918-929.
42. Martin-Ruiz CM, Court JA, Molnar E, Lee M, Gotti C, Mamalaki A, Tsouloufis T, Tzartos S, Ballard C, Perry RH, Perry EK (1999) Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. J Neurochem 73, 1635-1640. (Pubitemid 29440166)
43. Nordberg A (2001) Nicotinic receptor abnormalities of Alzheimer's disease: Therapeutic implications. Biol Psychiatry 49, 200-210. (Pubitemid 32178429)
44. Court J, Martin-Ruiz C, Piggott M, Spurden D, Griffiths M, Perry E (2001) Nicotinic receptor abnormalities in Alzheimer's disease. Biol Psychiatry 49, 175-184. (Pubitemid 32178426)
45. Ikonomovic MD,Wecker L, Abrahamson EE,Wuu J, Counts SE, Ginsberg SD, Mufson EJ, Dekosky ST (2009) Cortical alpha7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease. Arch Neurol 66, 646-651.
46. Teaktong T, Graham A, Court J, Perry R, Jaros E, Johnson M, Hall R, Perry E (2003) Alzheimer's disease is associated with a selective increase in alpha7 nicotinic acetylcholine receptor immunoreactivity in astrocytes. Glia 41, 207-211. (Pubitemid 36262198)
47. Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwig J, Albuquerque EX, ZerlinM(2001) Allosteric sensitization of nicotinic receptors by galantamine, a newtreatment strategy for Alzheimer's disease. Biol Psychiatry 49, 279-288. (Pubitemid 32178437)
48. Luttmann E, Ludwig J, Hoffle-Maas A, Samochocki M, Maelicke A, Fels G (2009) Structural model for the binding sites of allosterically potentiating ligands on nicotinic acetylcholine receptors. ChemMedChem 4, 1874-1882.
49. Unger C (2005) Effect of Subchronic Treatment of Memantine, Galantamine, and Nicotine in the Brain of Tg2576 (APPswe) Transgenic Mice. J Pharmacol Exp Ther 317, 30-36.
50. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL (2007) Abeta oligomers induce neuronal oxidative stress through an N-methyl-Daspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282, 11590-11601. (Pubitemid 47100810)
51. Klyubin I,Wang Q, Reed MN, Irving EA, Upton N, Hofmeister J, Cleary JP, Anwyl R,RowanMJ (2011) Protection against A-mediated rapid disruption of synaptic plasticity and memory by memantine. Neurobiol Aging 32, 614-623.
52. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL (2007) Abeta oligomerinduced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27, 796-807. (Pubitemid 46174498)
53. Wei W, Nguyen LN, Kessels HW, Hagiwara H, Sisodia S, Malinow R (2009) Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat Neurosci 13, 190-196.
54. Steele JW, Kim SH, Cirrito JR, Verges DK, Restivo JL,Westaway D, Fraser P, Hyslop PS, Sano M, Bezprozvanny I, Ehrlich ME, Holtzman DM, Gandy S (2009) Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo. Mol Neurodegener 4, 51.
55. Bachurin S, Bukatina E, Lermontova N, Tkachenko S, Afanasiev A, Grigoriev V, Grigorieva I, Ivanov Y, Sablin S, Zefirov N (2001) Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann N Y Acad Sci 939, 425-435. (Pubitemid 32620096)
56. Giorgetti M, Gibbons JA, Bernales S, Alfaro IE, Drieu La Rochelle C, Cremers T, Altar CA, Wronski R, Hutter-Paier B, Protter AA (2010) Cognition-Enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-aspartate receptor antagonism. J Pharmacol Exp Ther 333, 748-757.
57. Kihara T, Shimohama S, Sawada H, Kimura J, Kume T, Kochiyama H, Maeda T, Akaike A (1997) Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Ann Neurol 42, 159-163. (Pubitemid 27340459)
58. Wang HY, Stucky A, Liu J, Shen C, Trocme-Thibierge C, Morain P (2009) Dissociating beta-amyloid from alpha7 nicotinic acetylcholine receptor by a novel therapeutic agent, S 24795, normalizes alpha7 nicotinic acetylcholine andNMDA receptor function in Alzheimer's disease brain. J Neurosci 29, 10961-10973.
59. Hilt D, Gawryl M, Koenig G, Dgetluck N, Moebius HJ (2012) EVP-6124, a selective alpha-7 partial agonist, has positive effects on cognition and clinical function in mild to moderate Alzheimer's disease patients: Results of a sixmonth, double-blind, placebo controlled, dose ranging study. Alzheimer's Association International Conference, Vancouver, Canada.
60. Roncarati R, Scali C, Comery TA, Grauer SM, Aschmi S, Bothmann H, Jow B, Kowal D, Gianfriddo M, Kelley C, Zanelli U, Ghiron C, Haydar S, Dunlop J, Terstappen GC (2009) Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders. J Pharmacol Exp Ther 329, 459-468.
61. Bitner RS, Bunnelle WH, Decker MW, Drescher KU, Kohlhaas KL, Markosyan S, Marsh KC, Nikkel AL, Browman K, Radek R, Anderson DJ, Buccafusco J, Gopalakrishnan M (2010) In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: Preclinical considerations in Alzheimer's disease. J Pharmacol Exp Ther 334, 875-886.
62. Alafuzoff I, Iqbal K, Friden H, Adolfsson R, Winblad B (1987) Histopathological criteria for progressive dementia disorders: Clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol 74, 209-225. (Pubitemid 17142259)